12 results about "Enteral administration" patented technology

The present invention relates to immunoglobulin single variable domains (ISVDs) for the treatment of diseases by the enteral, e.g. oral, delivery. In particular, the present invention provides ISVDs comprising sequences with a high percentage of sequence identity to SEQ ID NO: 1 for such enteral administration. Such sequences were identified as extraordinarily stable in the gastrointestinal tract, which prevents their degradation and thereby allows them to exert a strong therapeutic effect.

The invention relates to a solid water-dispersible pharmaceutical composition for use in the treatment of a disease, said treatment comprising dispersing said pharmaceutical composition into an aqueous liquid to produce an enteraliy administrable liquid containing at least 0.5 gram of said pharmaceutical composition and at least 0.3 g / 1 of edaravone, followed by enteral administration of said enteraliy administrable liquid to a human patient in an amount to provide a dose of 30-300 mg of edaravone, said pharmaceutical composition comprising: 2-50 weight % of 3-methyl-l-phenyl-2-pyrazolin-5-one (edaravone); and 3-50 weight % of a water-soluble alkalizing agent. This solid composition containing edaravone can be easily dispersed in an aqueous liquid to prepare an aqueous solution of edaravone that can be ingested by a patient. The solid composition of the invention provides the advantage that when the composition is introduced into water the edaravone dissolves very rapidly and the enteraliy administrable liquid thus obtained has a high oral bioavailability.

The present invention relates to liquid pharmaceutical compositions of edaravone. More specifically, stable solutions of edaravone for enteral administration are provided, wherein the composition is stable for extended period of time. The present invention further relates to stable solutions of edaravone, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by edaravone.

The present invention relates to the field of stabilized biopolymer compositions, and in particular to stabilized biopolymer compositions comprising a liquid mixture, particularly an aqueous solution, of at least one biopolymer component and at least one stabilizing surfactant. More specifically, the present invention relates to stabilized biopolymer compositions comprising an ethylene oxide / butylene oxide block copolymer, which can impart superior properties to the biopolymer composition compared to currently known formulations, particularly with respect to aggregation tendency, hemolytic activity, and solubility. The present invention further relates to the block copolymer, a method for preparing the stabilized composition, and the use of the block copolymer to stabilize an aqueous composition of the biopolymer. The present invention further relates to the stabilized composition for use in medicine, particularly for diagnostic and / or therapeutic applications. The present invention further relates to an essentially dry biopolymer composition comprising the biopolymer and the block copolymer, and a method for preparing the essentially dry composition. The present invention further relates to the essentially dry biopolymer composition for use in medicine, particularly for diagnostic and / or therapeutic applications. The compositions may be formulated as pharmaceutical compositions that can be delivered via a suitable route of administration, such as oral, rectal, transmucosal, topical, ophthalmic, otorhinological, or enteral administration; parenteral delivery, including intramuscular, subcutaneous, intramedullary injection, and, in some cases, epidural, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injection.

The present invention relates to a specific lipid emulsion comprising ≥ 5 % stearidonic acid and ≥ 15 % α-linolenic acid for use in neuroprotection, neuroregeneration and neurodevelopment.

Described herein are methods and compositions for treatment of diabetes and / or obesity. Bitter oligopeptide molecules formulated for enteric delivery modulate signals involving receptors facing the lumen of the gastrointestinal tract, said signaling related hormones such as glucagon-like peptide-1 (GLP-1) and peptide tyrosine-tyrosine (PYY) that involve inhibition of gastric emptying and appetite. As a novel way to treat diabetes with limited adverse effects the described invention uses body's own endocrine system to treat diabetes, which is an advantage over current therapies that may simply provide disease management without cure or require more radical approaches such as surgical intervention.

The applicant discloses a method and composition for treating patients suffering from amyotrophic lateral sclerosis (ALS), comprising the administration of a heteroarylketone condensed azadecalin compound. In embodiments, the heteroarylketone condensed azadecalin compound is dazcholilant:(R)-(1-(4-fluorophenyl)-6-((4-(trifluoromethyl)phenyl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1-H-pyrazolo[3,4-g]isoquinoline-4a-yl)(pyridine-2-yl)methanone, which has the following chemical structure. Appropriate dosages include daily administration of 150 mg and 300 mg of dazcholant. Appropriate dosages also include daily administration of dazcholant with food, water, or food and water. Daily administration of dazcholant for seven days or more is effective in increasing exposure to dazcholant by approximately twofold. Administration of such heteroarylketone condensed azadecalin compounds may include oral administration, enteral administration, or other methods. Pharmaceutical compositions containing dazcholant are useful in the treatment of patients with ALS. Suitable pharmaceutical compositions containing dazcholant include, for example, pharmaceutical compositions for oral administration and pharmaceutical compositions for enteral administration. [Formula 1] JPEG2026509959000013.jpg4766

Applicant discloses methods and compositions for treating a patient suffering from amyotrophic lateral sclerosis (ALS) comprising administration of a heteroaryl ketone fused azadecalin compound. In embodiments, the heteroaryl ketone fused azadecalin compound is dazucorilant: (R)-(1-(4-fluorophenyl)-6-((4-(trifluoromethyl)phenyl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1-H-pyrazolo[3,4-g]isoquinolin-4a-yl)(pyridin-2-yl)methanone, having the chemical structure illustrated asSuitable doses include daily administration of 150 milligrams and 300 milligrams of dazucorilant. Suitable doses include daily administration of dazucorilant with food, or with water, or with food and water. Daily administration of dazucorilant is effective to increase dazucorilant exposure up to about 2-fold when continued for seven days or more. Administration of such a heteroaryl ketone fused azadecalin compound may comprise oral administration, enteral administration, or other administration. Pharmaceutical compositions comprising dazucorilant are useful in the treatment of patients suffering from ALS. Suitable pharmaceutical compositions comprising dazucorilant include, e.g., pharmaceutical compositions for oral administration and pharmaceutical compositions for enteral administration.

[Problem] To provide an anti-obstruction agent for enteral administration catheters that prevents contamination and blockage caused by oxidation of residual administered substances. [Solution] The anti-obstruction agent for enteral administration catheters is a gel-like substance characterized by being a hydrogel using water-soluble polysaccharides and / or water-soluble proteins. To prevent blockage due to oxidative contamination in the enteral administration catheter, the anti-obstruction agent for enteral administration catheters is filled into and retained in the enteral administration catheter to prevent blockage. [Selected Figure] None

The present invention relates to liquid pharmaceutical compositions of edaravone. More specifically, stable solutions of edaravone for enteral administration are provided, wherein the composition is stable for extended period of time. The present invention further relates to stable solutions of edaravone, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by edaravone.

A method of treating patients by using a pharmaceutical composition for intra-intestinal administration comprises (i) a dopamine replacement agents, (ii) a dopamine decarboxylase inhibitor (DDI), and (iii) a COMT inhibitor where the composition is continuously administrated.